Progressive Care Inc. RXMD
We take great care to ensure that the data presented and summarized in this overview for Progressive Care Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RXMD
Top Purchases
Top Sells
About RXMD
Progressive Care, Inc., through its subsidiary, Pharmco, LLC, provides prescription pharmaceuticals to individuals and institutions in south Florida. The company operates a retail pharmacy that specializes in the sale of anti-retroviral medications and related patient care management; the sale and rental of durable medical equipment (DME), such as hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories; and the supply of various prescription medications to long term care facilities. It also provides long term care solutions to skilled nursing facilities, assisted living facilities, retirement centers and communities, doctors' offices, and clinics. In addition, the company purchases, repackages, and dispenses prescription and non-prescription pharmaceutical products for its long term care customers. Further, it offers computerized maintenance of patient prescription histories; third party billing; consultant pharmacist services consisting of evaluation of monthly patient drug therapy and monitoring the institution's drug distribution system, as well as home service and maintenance, defective product replacements, and free home installation and instruction services; and data analytics services to support health care organizations. Progressive Care, Inc. was founded in 2005 and is based in Hallandale Beach, Florida.
Insider Transactions at RXMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 09
2023
|
Pedro Rodriguez Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,111
+25.97%
|
$44,444
$4.5 P/Share
|
|
Jul 21
2023
|
Jervis Hough Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,311
+17.81%
|
$46,555
$5.37 P/Share
|
|
Jul 01
2023
|
Charles M. Fernandez Chairman & CEO |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,443,839
+13.05%
|
$2,887,678
$2.2 P/Share
|
|
Jul 01
2023
|
Charles M. Fernandez Chairman & CEO |
SELL
Open market or private sale
|
Indirect |
600,100
-8.06%
|
$2,400,400
$4.45 P/Share
|
|
Jul 01
2023
|
Rodney Barreto Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,283,839
+11.57%
|
$2,567,678
$2.2 P/Share
|
|
Jul 01
2023
|
Rodney Barreto Director |
SELL
Open market or private sale
|
Indirect |
520,999
-7.02%
|
$1,562,997
$3.89 P/Share
|
|
May 09
2023
|
Charles M. Fernandez Chairman & CEO |
BUY
Conversion of derivative security
|
Indirect |
798,839
+36.48%
|
$1,597,678
$2.2 P/Share
|
|
May 09
2023
|
Charles M. Fernandez Chairman & CEO |
BUY
Open market or private purchase
|
Indirect |
455,000
+37.49%
|
$910,000
$2.2 P/Share
|
|
May 09
2023
|
Rodney Barreto Director |
BUY
Conversion of derivative security
|
Indirect |
798,839
+35.77%
|
$1,597,678
$2.2 P/Share
|
|
May 09
2023
|
Rodney Barreto Director |
BUY
Open market or private purchase
|
Indirect |
455,000
+37.04%
|
$910,000
$2.2 P/Share
|
|
Apr 18
2023
|
Pedro Rodriguez Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+42.19%
|
$45,000
$3.16 P/Share
|
|
Apr 18
2023
|
Joseph Ziegler Director |
BUY
Grant, award, or other acquisition
|
Indirect |
15,000
+39.27%
|
$45,000
$3.16 P/Share
|
|
Jan 01
2023
|
Joseph Ziegler Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,197
+50.0%
|
$49,182
$6.1 P/Share
|
|
Oct 07
2022
|
Alan Jay Weisberg Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000,000
+37.17%
|
-
|
|
Oct 07
2022
|
Birute Norkute Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000,000
+38.13%
|
-
|
|
Jul 21
2022
|
Jervis Hough Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,929
+32.38%
|
$44,645
$5.6 P/Share
|
|
Apr 05
2022
|
Jervis Hough Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+30.84%
|
$45,000
$3.16 P/Share
|
|
Mar 22
2022
|
Joseph Ziegler Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,929
+50.0%
|
$44,645
$5.6 P/Share
|
|
Dec 14
2021
|
Alan Jay Weisberg Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
277,528
+3.14%
|
$0
$0.03 P/Share
|
|
Dec 13
2021
|
Alan Jay Weisberg Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
437,451
+5.01%
|
$0
$0.03 P/Share
|